State Fees for Medical Device Registration in Russia Under Tax Code Article 333.32.2
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The state fees for the national registration of medical devices are set by Article 333.32.2 of the Tax Code of the Russian Federation and consist of three components: the certificate and register entry, an expert review fee tiered by the potential application risk class, and fees for changes and duplicates. The current figures are: certificate 11,000 rubles; expert review level 1: 72,000, level 2а: 104,000, level 2б: 136,000, level 3: 184,000 rubles; a change not requiring expert review 2,500 rubles; a change requiring expert review 32,000 / 48,000 / 64,000 / 104,000 rubles; and a duplicate 2,500 rubles. Because the risk class is assigned early in the project, the expert review tier, and therefore a large part of the statutory budget, is effectively determined by the classification decision made at the very start of the registration program.
For budgeting purposes, the fees are the only fully predictable element of the Russian registration budget. Testing, clinical work, translation and representative services are quoted at market rates and vary with the product and the laboratory, while the state fees are fixed by the Tax Code. Any budget that misstates the fees, or relies on outdated figures circulating online, creates an error that propagates through the whole project financial plan and into the internal approval chain.
2. Legal basis
The fee schedule rests on the Tax Code, while the procedures to which the fees attach are defined in the national registration rules and the nomenclature classification. The table below lists the instruments relied on in this article, with reference numbers, dates and the provisions relevant to the fees.
| Legal act | Reference | Date | Provisions |
|---|---|---|---|
| Tax Code of the Russian Federation | Article 333.32.2 of the Tax Code of the Russian Federation | current version | state fees for the national registration of medical devices |
| Government Resolution of the Russian Federation on the National Rules for the State Registration of Medical Devices | Government Resolution No. 1684 | 30 November 2024 | para. 5, paras. 111 and 114 to 132 (procedure stages corresponding to the fees) |
| Government Resolution of the Russian Federation extending the validity of the rules | Government Resolution No. 2214 | 30 December 2025 | the rules remain in force until 31 December 2028 |
| Order of the Ministry of Health on the nomenclature classification of medical devices | Order of the Ministry of Health of Russia No. 4n | 6 June 2012 | the class determination decides the fee tier |
Note: the fee amounts follow the current text of the Tax Code. Outdated pre-amendment figures still circulate online (such as 7,000 / 45,000 / 65,000 / 85,000 / 115,000 rubles); they are not adopted here. Before any payment, rely on the current online calculation of the tax authority.
3. Expert insights
Insight one: the class determines the review fee, not the total cost. The expert review fee is only the fixed component. Testing, clinical work, translation and notarization, and authorized representative services usually constitute a larger share of the budget. Treating the review fee as the main budget line is a common estimation error, particularly for companies entering Russia for the first time and anchoring their financial plan on the statutory numbers alone. A realistic budget separates the fixed statutory component from the variable market-priced components and reviews the latter at each project gate.
Insight two: the choice of change route has financial consequences. A change that does not require expert review costs only 2,500 rubles, while a change requiring expert review costs between 32,000 and 104,000 rubles depending on the class. Where the arguments allow a change to be routed under para. 111, the saving is significant, and the routing analysis is worth performing before filing rather than after. Over the life of a certificate, with several changes per year across a portfolio, the difference between the two routes compounds into a material budget line.
Insight three: fees are charged per project, not per successful outcome. The fees are not refunded whether or not the certificate is granted; a refiling after revocation requires a fresh payment. The strategy of filing once to see what happens is therefore not economical in Russia. A front-loaded completeness and consistency review of the dossier costs far less than a failed cycle, both in fees and in the calendar time consumed by a rejected or suspended procedure.
Insight four: the old figures remain a live trap. Pre-amendment amounts still appear in older publications and in some vendor presentations. Any budget document that carries a figure inconsistent with Article 333.32.2 should be corrected before submission to finance, since a payment against a wrong amount can stall the acceptance of the application.
4. Practical recommendations
The measures below keep the statutory fee component of the budget accurate and auditable across the portfolio. They are intended for regulatory, finance and procurement teams working jointly on Russian registration projects.
- List the state fees as a separate line in the budget, marked as subject to the current text of the Tax Code, and leave room for adjustments in the financial plan.
- Maintain a fee ledger for each registration unit: record the initial registration fee, change fees and duplicate fees in separate accounts.
- Before each filing, verify that the payment details match the registration details, so the payment is not returned for incomplete payer attributes.
- Recheck the current amounts on the tax authority calculation service at every payment, and update internal templates whenever the Tax Code text changes.
5. Verification checklist
Confirm each item below before submitting fees or approving a registration budget. Each item guards against one of the errors described above.
- □ The expert review fee tier has been determined according to the class of the product
- □ The certificate fee of 11,000 rubles has been budgeted as a separate line
- □ The change route (with or without expert review) and the corresponding fee have been anticipated
- □ The current amounts under the Tax Code have been rechecked before payment
- □ The fee ledger covers initial registration, changes and duplicates
Regulatory information verified as of 29 October 2026.
GRZAN provides budget support for medical device registration in Russia: building itemized fee schedules under Article 333.32.2, maintaining fee ledgers across the certificate portfolio, and advising on change routing to keep statutory costs under control. For a fee budget review, contact GRZAN at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us